Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1

Three scientists win Nobel Prize in chemistry for creating new molecular structure

Boehringer bags FDA okay for new pulmonary fibrosis drug

CAMBRIDGE, Mass. - Editas Medicine, Inc., whose stock has surged over 260% in the past six months according to InvestingPro data

China-based companies are responsible for 20% of drugs in development globally, reflecting the powerhouse role the country has embraced in the pharmaceutical industry.